The GS-441524 Remdesivir metabolite alongside ADP-ribose; HCV drug BOC binding to the NSP5 protease binding pocket. In the search for new ways to use small molecule drugs to prevent and treat Covid-19 ...
Small Molecule Combination Therapies Are Being Investigated to Increase Response Rates Researchers agree that now is a crucial time to be involved in hepatitis C virus (HCV) research. “Current ...
Remdesivir, the only antiviral drug approved in the United States for treating COVID-19 patients, is up to 10 times more effective when it is mixed with a repurposed hepatitis C drug. The effect has ...
SARS-CoV-2 has infected over 71.5 million people and claimed over 1.6 million lives globally since December 2019. The mitigation strategies implemented worldwide have slowed down the pace of this ...
FDA Approves Merck's VICTRELIS (boceprevir), First-in-Class Oral Hepatitis C Virus (HCV) Protease Inhibitor WHITEHOUSE STATION, N.J., May 13, 2011 - Merck (NYSE:MRK) (known as MSD outside the United ...
The FDA is notifying health-care professionals about potential dangerous drug interactions between the hepatitis C virus (HCV) protease inhibitor boceprevir (Victrelis, Merck) and certain anti-HIV ...
Findings showed that in patients treated with glecaprevir/pibrentasvir, the overall SVR12 rate was 96%, with 0 patients experiencing virologic failure. The Food and ...
NEW HAVEN, Conn., March 16, 2011 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging ...
"In patients with chronic infection with [HCV] genotype 1 who do not have a sustained response to therapy with peginterferon–ribavirin, outcomes after retreatment are suboptimal," write Bruce R. Bacon ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results